Xin Lang Cai Jing·2025-11-20 08:47Core Viewpoint - Fosun Pharma's subsidiary has developed a novel drug, Sruvulimab injection, for the treatment of gastric cancer, which has been included in the breakthrough therapy designation program, potentially accelerating its review and market entry [1] Group 1: Drug Development and Approval - Sruvulimab injection is being used in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer [1] - As of November 20, 2025, the drug has received approval in multiple countries/regions, with several combination therapies currently undergoing clinical trials [1] - The total R&D investment in the drug has reached approximately 3.495 billion yuan as of October 2025 [1] Group 2: Market Potential - There are currently no approved PD-1 targeted monoclonal antibodies for neoadjuvant/adjuvant treatment of gastric cancer globally [1] - The global sales for such drugs are projected to be approximately 45.704 billion USD in 2024 [1] - The inclusion in the breakthrough therapy program is expected to expedite the drug's review and market entry, although uncertainties remain regarding the new drug's launch [1]